Foseco India Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹252 Cr +66.9% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
F

Foseco India Ltd

Q1 FY27Chemicals & Petrochemicals

Foseco India Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹231Cr
+55% YoY
+14.4% QoQ
Net profit
₹36Cr
+63.6% YoY
+9.1% QoQ
Margin
23%
+5 pp YoY
+3 pp QoQ

Based on Foseco India Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹6,468
Market cap₹5.0K Cr
P/E48.3

The short version

Q2 CY26 Revenue: INR 231.4 Cr (Page 9) - H1 CY26 Revenue: INR 433.3 Cr, up 41.7% YoY (Page 9) - H1 CY25 Revenue: INR 305.8 Cr (Page 9) - Q1 CY26 Revenue: INR 201.9 Cr (Page 9) - CY25 Revenue: INR 643.4 Cr, 22.6% growth over CY24 (Page 9) - Quarterly EBITDA (Q2 CY26): INR 58.3 Cr, with a margin of 25.2% (Page 9) - Year-on-Year EBITDA Growth: Up from INR 49.7 Cr and 14.6% margin in Q2 CY25 to 58.3 Cr and 25.2% margin in Q2 CY26 (i

From Foseco India Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q2 CY26 Revenue: INR 231.4 Cr (Page 9)
  • H1 CY26 Revenue: INR 433.3 Cr, up 41.7% YoY (Page 9)
  • H1 CY25 Revenue: INR 305.8 Cr (Page 9)
  • Q1 CY26 Revenue: INR 201.9 Cr (Page 9)
  • CY25 Revenue: INR 643.4 Cr, 22.6% growth over CY24 (Page 9)

2 more points from Foseco India Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Foseco India Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Acquisition of Mehsana (Gujarat) manufacturing facility from Vesuvius India Limited by slump sale; INR 43.25 Cr lump sum cash consideration; expected completion by 31 December 2026; requires GIDC approval and other regulatory clearances (Page 21).
  • Mention of focused capex to strengthen operational excellence, aiming for faster turnaround, reliable fulfillment, lower cost to serve (Page 23).
  • Installed in-house solar energy source of 565 kWP to support sustainability goals (Page 25).

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Foseco India Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Foseco India Ltd said on order book & pipeline — free account, 30 seconds.

Foseco India Ltd — Quarterly revenue & net profit

Revenue Net profit
Mar 2025Q4 FY25
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Foseco India Ltd Q1 FY27 results — key figures

Foseco India Ltd Q1 FY27 reported results vs Q4 FY25, ₹ crore
₹ CrQ1 FY27Q4 FY25YoYQ4 FY26QoQ
Revenue231149+55%202+14.4%
Operating profit (EBITDA)5327+96.3%41+29.3%
Operating margin23%18%+5 pp20%+3 pp
Profit before tax5029+72.4%44+13.6%
Net profit (PAT)3622+63.6%33+9.1%
EPS (₹)44.7433.93+31.9%41.50+7.8%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹252 Cr, net profit ₹40 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Foseco India's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Alufluoride (Q1 FY27)

    Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr

  • POCL Enterprises (Q1 FY27)

    466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto

  • Devson Catalyst (Q1 FY27)

    FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee

  • Ambani Orgochem (Q1 FY27)

    Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Foseco India Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Foseco India Ltd Q1 FY27 results?

Q2 CY26 Revenue: INR 231.4 Cr (Page 9) - H1 CY26 Revenue: INR 433.3 Cr, up 41.7% YoY (Page 9) - H1 CY25 Revenue: INR 305.8 Cr (Page 9) - Q1 CY26 Revenue: INR 201.9 Cr (Page 9) - CY25 Revenue: INR 643.4 Cr, 22.6% growth over CY24 (Page 9) - Quarterly EBITDA (Q2 CY26): INR 58.3 Cr, with a margin of 25.2% (Page 9) - Year-on-Year EBITDA Growth: Up from INR 49.7 Cr and 14.6% margin in Q2 CY25 to 58.3 Cr and 25.2% margin in Q2 CY26 (i

What is Foseco India Ltd share price analysis?

Foseco India Ltd currently shows a neutral. The stock trades at a P/E of 48.3 with a market cap of ₹5,033 Cr. Investors should review the full earnings analysis for detailed insights.

Is Foseco India Ltd planning capital expenditure?

Acquisition of Mehsana (Gujarat) manufacturing facility from Vesuvius India Limited by slump sale; INR 43.25 Cr lump sum cash consideration; expected completion by 31 December 2026; requires GIDC approval and other regulatory clearances (Page 21).

Keep Foseco India Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.